President Donald Trump is set to announce on Friday that all 50 states, Washington D.C., and Puerto Rico will participate in a federal program to lower prescription drug prices for Medicaid programs. The initiative, referred to as the Medicaid ‘Most Favored Nation’ model, aims to align U.S. drug prices with the lowest prices paid in other high-income countries for selected medications.
The White House states the expansion will apply to selected prescription drugs within Medicaid, with pricing tied to the lowest prices negotiated by the administration with pharmaceutical companies. Officials estimate the policy could reduce costs for Medicaid programs, though the exact financial impact remains undisclosed. The announcement follows an executive order signed last year establishing the ‘Most Favored Nation’ policy, which commits the U.S. to paying no more for certain drugs than the lowest price paid in other nations.
How the policy works
The program, first introduced in May, allows the federal government to negotiate drug prices for Medicaid on behalf of all participating states. Under the model, the price of specific drugs in the U.S. would not exceed the lowest price charged in countries including Canada, Germany, and Japan. The administration has not released the full list of drugs or the terms of the agreements with pharmaceutical companies.
Reactions and uncertainties
Experts and policymakers have raised questions about the long-term savings and implementation. While the White House has projected billions in potential savings, critics note that the actual cost reductions depend on undisclosed negotiations. The policy’s impact on drug accessibility and manufacturer incentives remains a subject of debate.
The announcement coincides with heightened public concern over rising healthcare costs ahead of the November midterm elections. The administration frames the initiative as a step toward reducing prescription drug expenses for American taxpayers and Medicaid beneficiaries. The expansion of the model to all states marks a significant scaling of the policy, which previously applied to a limited number of jurisdictions.